甲基酸盐缓解了早期接触所引起的认知功能障碍:儿科胺基体受体的作用
Stephane A Beaudin1, Shanna Howard1, Nicholas Santiago1
1Department of Microbiology and Environmental Toxicology, University of California, Santa Cruz, CA, USA.
Progress in neuro-psychopharmacology & biological psychiatry
|January 24, 2024
概括
甲基 (MPH) 有效地治疗了小鼠在发育过程中接触 (Mn) 引起的注意力和感觉运动缺陷. MPH显示剂量依赖的疗效,突出其治疗环境诱导的神经发育障碍的潜力.
科学领域:
- 神经科学是一个神经科学.
- 环境健康 环境健康
- 药理学 药理学是指药理学的学科.
背景情况:
- 环境 (Mn) 暴露与儿童的注意力和精神运动缺陷有关.
- 发育性Mn暴露会在老鼠模型中诱导类似的功能障碍.
- 甲基化物 (MPH) 改善了儿童的注意力和精神运动功能,但其对Mn诱导的缺陷的有效性尚不清楚.
研究的目的:
- 为了确定口服的MPH治疗是否能改善从发育期接触到的持续注意力和感觉运动障碍.
- 在这种情况下,阐明神经毒性和MPH有效性的机制.
主要方法:
- 大鼠在出生后的1-21天内口服 (50毫克/公斤/天).
- 在MPH治疗期间 (0-3.0 mg/kg/d) 评估了成年大鼠的注意力,冲动控制和感觉运动任务.
- 甲基荷胺基受体对抗剂被用于探索神经毒性和MPH作用的机制.
主要成果:
- 发育期的Mn暴露导致持续的注意力和感觉运动障碍.
- MPH (0.5 mg/kg/d) 完全改善了注意力缺陷;较高剂量 (3.0 mg/kg/d) 改善了感觉运动缺陷.
- D2受体对抗性降低了Mn感觉运动缺陷,而D1受体对抗性降低了MPH对这些缺陷的有效性.
结论:
- MPH有效地缓解了由发育性Mn暴露引起的持久注意力和感觉运动功能障碍.
- 这些发现澄清了Mn神经毒性和MPH疗效的机制,涉及特定的甲醇胺基通路.
- 结果对治疗儿童中环境诱导的神经发育障碍有影响.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
126
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
126
Attention-Deficit/Hyperactivity Disorder
68
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
68
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K


